



Medications for Insomnia:

Drug Information to Support Drug Therapy Decisions

B.C. Provincial Academic Detailing (PAD) Service

December 2020

References

Prescribing Principles

1. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
2. Sateia M, Buysse D, Krystal A, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Sleep Med* 2017;13:307-49. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27998379/>
3. Qaseem A, Kansagara D, Forcica M, et al. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2016;165:125-33. [Internet]. <https://www.acpjournals.org/doi/10.7326/M15-2175>
4. Health Canada. Drug Product Database. [Internet].
Imovane (zopiclone). https://pdf.hres.ca/dpd_pm/00058189.PDF
Lunesta (eszopiclone). https://pdf.hres.ca/dpd_pm/00055610.PDF
Sublinox (zolpidem). https://pdf.hres.ca/dpd_pm/00052044.PDF
5. US Food and Drug Administration. Drugs@FDA. Silenor (doxepin). NDA 022036. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036Orig1s000MedR.pdf
6. US Food and Drug Administration. Drugs@FDA. Dayvigo (lemborexant). NDA 212028. Multidisciplinary Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf
7. Therapeutics Initiative. To sleep or not to sleep: here are your questions. *Therapeutics Letter* 11. 1995. [Internet]. <https://www.ti.ubc.ca/pages/letter11.html>
8. Canadian Coalition for Seniors' Mental Health. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. 2019. [Internet]. https://ccsmh.ca/wp-content/uploads/2019/11/Benzodiazepine_Receptor_Agonist_Use_Disorder_ENG.pdf
9. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists. Evidence-based clinical practice guideline. *Can Fam Phys* 2018;64:339-51. [Internet]. <https://deprescribing.org/resources/deprescribing-guidelines-algorithms/>

Zopiclone, Eszopiclone, Zolpidem

1. Health Canada. Drug Product Database. [Internet].
Imovane (zopiclone). https://pdf.hres.ca/dpd_pm/00058189.PDF
Lunesta (eszopiclone). https://pdf.hres.ca/dpd_pm/00055610.PDF
Sublinox (zolpidem). https://pdf.hres.ca/dpd_pm/00052044.PDF
2. Agency for Healthcare Research and Quality (US). Manifestations and Management of Chronic Insomnia in Adults. 2005. [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK37868/>
3. Rosner S, Englbrecht C, Wehrle R, et al. Eszopiclone for insomnia (Review). *Cochrane Database Syst Reviews* 2018, Issue 10. Art. No.: CD010703. [Internet]. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010703.pub2/epdf/full>
4. College of Physicians and Surgeons of British Columbia. Practice Standards. 2019. Safe Prescribing of Opioids and Sedatives. Version 4.2. [Internet]. <https://www.cpsbc.ca/files/pdf/PSG-Safe-Prescribing.pdf>
5. US Food and Drug Administration. 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. [Internet]. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
6. Health Canada. 2020. Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74223a-eng.php>
7. Health Canada. 2014. Imovane (zopiclone) new dosage recommendations to minimize the risk of next day impairment. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/42253a-eng.php>
8. Health Canada. 2014. Sublinox (zolpidem) new dosage recommendations to minimize the risk of next day impairment in both women and men. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/37415a-eng.php>
9. US Food and Drug Administration. 2013. Ambien (zolpidem) FDA approves new label changes and dosing for zolpidem products and a recommendation to avoid driving the day after using Ambien CR. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-new-label-changes-and-dosing-zolpidem-products-and>
10. US Food and Drug Administration. 2014. Lunesta (eszopiclone) FDA warns of next day impairment and lowers recommended dose. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-next-day-impairment-sleep-aid-lunesta-eszopiclone-and-lowers>

11. Brandt J, Leong C. Benzodiazepines and Z-Drugs: An updated review of major adverse outcomes reported on in epidemiologic research. *Drugs* 2017;17:493-507. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/28865038/>
12. Health Canada. 2011. Sublinox (zolpidem) association with complex sleep behaviours. [Internet]. <https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2011/14663a-eng.php>
13. US Food and Drug Administration. 2019. FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medications. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia>
14. Canadian Coalition for Seniors' Mental Health. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. 2019. [Internet]. https://ccsmh.ca/wp-content/uploads/2019/11/Benzodiazepine_Receptor_Agonist_Use_Disorder_ENG.pdf
15. US Food and Drug Administration. Drugs@FDA. [Internet].
Lunesta (eszopiclone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021476Orig1s038rplLBL.pdf
Ambien (zolpidem). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019908s046lbl.pdf
16. McKesson Canada. [Internet]. <https://www.mckesson.ca/>

Temazepam, Oxazepam

1. Health Canada. Drug Product Database. [Internet].
Restoril (temazepam). https://pdf.hres.ca/dpd_pm/00045030.PDF
Riva-oxazepam. https://pdf.hres.ca/dpd_pm/00038954.PDF
2. Agency for Healthcare Research and Quality (US). 2005. Manifestations and Management of Chronic Insomnia in Adults. [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK37868/>
3. College of Physicians and Surgeons of British Columbia. Practice Standards. 2019. Safe Prescribing of Opioids and Sedatives. Version 4.2. [Internet]. <https://www.cpsbc.ca/files/pdf/PSG-Safe-Prescribing.pdf>
4. US Food and Drug Administration. 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. [Internet]. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
5. Health Canada. 2020. Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74223a-eng.php>
6. US Food and Drug Administration. 2020. FDA requiring boxed warning update to improve safe use of benzodiazepine drug class. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class>
7. Brandt J, Leong C. Benzodiazepines and Z-Drugs: An updated review of major adverse outcomes reported on in epidemiologic research. *Drugs* 2017;17:493-507. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/28865038/>
8. Canadian Coalition for Seniors' Mental Health. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. 2019. [Internet]. https://ccsmh.ca/wp-content/uploads/2019/11/Benzodiazepine_Receptor_Agonist_Use_Disorder_ENG.pdf
9. US Food and Drug Administration. Drugs@FDA. [Internet].
Restoril (temazepam). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018163s065lbl.pdf
Serax (oxazepam). https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/15539s52lbl.pdf
10. McKesson Canada. [Internet]. <https://www.mckesson.ca/>

Doxepin

1. Health Canada. Drug Product Database. [Internet]. Silenor (doxepin). https://pdf.hres.ca/dpd_pm/00018598.PDF
2. Sateia M, Buysse D, Krystal A, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Sleep Med* 2017;13:307-49. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27998379/>
3. US Food and Drug Administration. Drugs@FDA. Silenor (doxepin). NDA 022036. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022036Orig1s000MedR.pdf
4. US Food and Drug Administration. Drugs@FDA. [Internet]. Silenor (doxepin). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022036s006lbl.pdf
5. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
6. McKesson Canada. [Internet]. <https://www.mckesson.ca/>

Amitriptyline, Mirtazapine, Trazodone, Quetiapine

1. Health Canada. Drug Product Database. [Internet].
Elavil (amitriptyline). https://pdf.hres.ca/dpd_pm/00047240.PDF
Remeron (mirtazapine). https://pdf.hres.ca/dpd_pm/00056551.PDF
Desyrel (trazodone). https://pdf.hres.ca/dpd_pm/00003350.PDF
Seroquel (quetiapine). https://pdf.hres.ca/dpd_pm/00054331.PDF

2. Sateia M, Buysse D, Krystal A, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Sleep Med* 2017;13:307-49. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27998379/>
3. Everitt H, Baldwin D, Stuart B, et al. Antidepressants for insomnia (Review). *Cochrane Database Syst Reviews* 2018, Issue 5. Art. No.:CD010753. [Internet]. <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010753.pub2/full>
4. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
5. Agency for Healthcare Research and Quality (US). 2005. Manifestations and management of chronic insomnia in adults. [Internet]. <https://www.ncbi.nlm.nih.gov/books/NBK37868/>
6. Agency for Healthcare Research and Quality (US). 2015. Management of insomnia disorder. [Internet]. <https://effectivehealthcare.ahrq.gov/products/insomnia/research>
7. Canadian Agency for Drugs and Technology in Health. 2018. Clinical evaluation of interventions for the management of insomnia: a review of reviews. [Internet]. https://www.cadth.ca/sites/default/files/pdf/op0527_insomnia_clinical-evaluation-corrected.pdf
8. Choosing Wisely Canada. Psychiatry. 2020. Thirteen things physicians and patients should question. [Internet]. <https://choosingwiselycanada.org/psychiatry/>
9. Pucci M, Roussak P, Pang D, Darrad M. Drug-induced priapism. *Adverse Drug Reaction Bulletin* 2020;322:1247-50. [Internet]. <https://insights.ovid.com/adverse-drug-reaction-bulletin/adrb/2020/06/000/drug-induced-priapism/1/00012995>
10. Watt J, Gomes T, Bronskill S, et al. Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. *CMAJ* 2018;190:E1376-83. [Internet]. <https://www.cmaj.ca/content/190/47/E1376>
11. Bronskill S, Campitelli M, Iaboni A, et al. Low-dose trazodone, benzodiazepines, and fall-related injuries in nursing homes: a matched-cohort study. *J Am Geriatr Soc* 2018;66:1963-71. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/30247773/>
12. Health Canada. 2005. Atypical antipsychotic drugs and dementia. [Internet]. <https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2005/14307a-eng.php>
13. Health Canada. 2016. Atypical antipsychotics assessing the potential risk of sleep apnoea. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-sleep-apnoea.html>
14. US Food and Drug Administration. 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. [Internet]. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
15. Health Canada. 2016. Atypical antipsychotics assessing the potential risk of urinary retention. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/summary-safety-review-atypical-antipsychotics-assessing-potential-risk-urinary-retention.html>
16. Coe H, Hong I. Safety of low dose quetiapine when used for insomnia. *Ann Pharmacother* 2012;46:718-22. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/22510671/>
17. US Food and Drug Administration. Drugs@FDA. [Internet].
Desyrel (trazodone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018207s033lbl.pdf
Seroquel (quetiapine). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020639s070lbl.pdf

Lemborexant

1. Health Canada. Drug Product Database. [Internet]. Dayvigo (lemborexant). https://pdf.hres.ca/dpd_pm/00058592.PDF
2. US Food and Drug Administration. Drugs@FDA. [Internet]. Dayvigo (lemborexant). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212028s002lbl.pdf
3. US Food and Drug Administration. Drugs@FDA. Dayvigo (lemborexant). NDA 212028. Multidisciplinary Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf
4. US Food and Drug Administration. 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. [Internet]. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
5. McKesson Canada. [Internet]. <https://www.mckesson.ca/>

Drug Interactions

1. Health Canada. Drug Product Database. [Internet].
Imovane (zopiclone). https://pdf.hres.ca/dpd_pm/00058189.PDF
Lunesta (eszopiclone). https://pdf.hres.ca/dpd_pm/00055610.PDF
Sublinox (zolpidem). https://pdf.hres.ca/dpd_pm/00052044.PDF
Restoril (temazepam). https://pdf.hres.ca/dpd_pm/00045030.PDF
Riva-oxazepam. https://pdf.hres.ca/dpd_pm/00038954.PDF
Elavil (amitriptyline). https://pdf.hres.ca/dpd_pm/00047240.PDF
Silenor (doxepin). https://pdf.hres.ca/dpd_pm/00018598.PDF

- Remeron (mirtazapine). https://pdf.hres.ca/dpd_pm/00056551.PDF
 Desyrel (trazodone). https://pdf.hres.ca/dpd_pm/00003350.PDF
 Seroquel (quetiapine). https://pdf.hres.ca/dpd_pm/00054331.PDF
 Dayvigo (lemborexant). https://pdf.hres.ca/dpd_pm/00058592.PDF
2. US Food and Drug Administration. Drugs@FDA. [Internet].
 Lunesta (eszopiclone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021476Orig1s038rplLBL.pdf
 Ambien (zolpidem). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019908s046lbl.pdf
 Restoril (temazepam). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018163s065lbl.pdf
 Serax (oxazepam). https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/15539s52lbl.pdf
 Silenor (doxepin). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022036s006lbl.pdf
 Remeron (mirtazapine).
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020415s034s036,021208s024s026lbl.pdf
 Desyrel (trazodone). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/018207s033lbl.pdf
 Seroquel (quetiapine). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020639s070lbl.pdf
 Dayvigo (lemborexant). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212028s002lbl.pdf
 3. Lexicomp®. [Internet]. <https://online.lexi.com/lco/action/home>
 4. US Food and Drug Administration. 2016. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use. [Internet]. <https://www.fda.gov/news-events/press-announcements/fda-requires-strong-warnings-opioid-analgesics-prescription-opioid-cough-products-and-benzodiazepine>
 5. Health Canada. 2020. Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74223a-eng.php>
 6. Indiana University. Cytochrome P450 Drug Interactions Flockhart Table. [Internet]. <https://drug-interactions.medicine.iu.edu/MainTable.aspx>
 7. US Food and Drug Administration. 2019. FDA adds boxed warning for risk of serious injuries caused by sleepwalking with certain prescription insomnia medications. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-boxed-warning-risk-serious-injuries-caused-sleepwalking-certain-prescription-insomnia>
 8. US Food and Drug Administration. Drugs@FDA. Dayvigo (lemborexant). NDA 212028. Multidisciplinary Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212028Orig1s000MultidisciplineR.pdf
 9. US Food and Drug Administration. 2020. Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. [Internet]. <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers#table5-2>
 10. Credible Meds. [Internet]. <https://crediblemeds.org/>

Non-Pharmacologic Strategies

1. Qaseem A, Kansagara D, Forcica M, et al. Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2016;165:125-33. [Internet]. <https://www.acpjournals.org/doi/10.7326/M15-2175>
2. Toward Optimized Practice. Assessment and management of adult insomnia. Clinical practice guideline. 2015. [Internet]. <https://act.albertadoctors.org/CPGs/Lists/CPGDocumentList/Adult-Insomnia-CPG.pdf>
3. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
4. Morgenthaler T, Kramer M, Alessi C, et al. Practice parameters for the psychological and behavioural treatment of insomnia: an update. *An American Academy of Sleep Medicine Report. Sleep* 2006;29:1415-19. [Internet]. https://j2vjt3dnbra3ps7ll1clb4q2-wpengine.netdna-ssl.com/wp-content/uploads/2017/07/PP_BTInsomnia_Update.pdf
5. Agency for Healthcare Research and Quality (US). 2015. Management of insomnia disorder. [Internet]. <https://effectivehealthcare.ahrq.gov/products/insomnia/research>
6. Canadian Agency for Drugs and Technology in Health. 2018. Clinical evaluation of interventions for the management of insomnia: a review of reviews. [Internet]. https://www.cadth.ca/sites/default/files/pdf/op0527_insomnia_clinical-evaluation-corrected.pdf
7. Kelty's Key. Vancouver Coastal Health. Insomnia. [Internet]. <https://www.keltyskey.com/courses/insomnia/>
8. South Australia Drug and Alcohol Service. Insomnia management kit. [Internet]. <https://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/services/mental+health+and+drug+and+alcohol+services/drug+and+alcohol+services/for+health+professionals+dassa/sleep+problems+-+insomnia+management+kit>

Tapering and Deprescribing

1. Health Canada. 2020. Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs. [Internet]. <https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74223a-eng.php>

2. US Food and Drug Administration. 2020. FDA requiring boxed warning update to improve safe use of benzodiazepine drug class. [Internet]. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-requiring-boxed-warning-updated-improve-safe-use-benzodiazepine-drug-class>
3. College of Physicians and Surgeons of British Columbia. Practice Standards. 2019. Safe Prescribing of Opioids and Sedatives. Version 4.2. [Internet]. <https://www.cpsbc.ca/files/pdf/PSG-Safe-Prescribing.pdf>
4. Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists. Evidence-based clinical practice guideline. *Can Fam Phys* 2018;64:339-51. [Internet]. <https://deprescribing.org/resources/deprescribing-guidelines-algorithms/>
5. Canadian Coalition for Seniors' Mental Health. Canadian Guidelines on Benzodiazepine Receptor Agonist Use Disorder Among Older Adults. 2019. [Internet]. https://ccsmh.ca/wp-content/uploads/2019/11/Benzodiazepine_Receptor_Agonist_Use_Disorder_ENG.pdf
6. Paquin A, Zimmerman K, Rudolph J. Risk versus risk: a review of benzodiazepine reduction in older adults. *Expert Opin Drug Saf* 2014;13:919-34. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/24905348/>
7. Ashton H. The Ashton Manual. Benzodiazepines: How they work and how to withdraw. 2002. [Internet]. <https://benzo.org.uk/manual/>
8. Benzodiazepine Information Coalition. [Internet]. <https://www.benzoinfo.com/>
9. Inner Compass Initiative. The Withdrawal Project. [Internet]. <https://withdrawal.theinnercompass.org/>
10. BenzoBuddies. Benzodiazepine Withdrawal Support. [Internet]. <http://www.benzobuddies.org/>

Medication Review for Possible Prescribing Cascades

1. Wolkove N, Elkholly O, Baltzan M, Palayew. Sleep and aging. Sleep disorders commonly found in older people. *CMAJ* 2007;176:1299-304. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/17452665/>
2. Schutte-Rodin S, Broch L, Buysse L, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. *J Clin Sleep Med* 2008;4:487-504. [Internet]. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2576317/>
3. Kaiser Permanente. Insomnia Guideline. 2019. [Internet]. <https://wa.kaiserpermanente.org/static/pdf/public/guidelines/insomnia.pdf>
4. Centre for Effective Practice. Chronic Insomnia. [Internet]. <https://cep.health/clinical-products/insomnia-management-of-chronic-insomnia-tool/>
5. Stein M, Friedmann P. Disturbed sleep and its relationship to alcohol use. *Subst Abus* 2005;26:1-13. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/16492658/>
6. Doufas A, Panagiotou O, Panousis P, et al. Insomnia from drug treatments: Evidence from meta-analyses of randomized trials and concordance with prescribing information. *Mayo Clin Proc* 2017;92:72-87. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27842706/>
7. RxFiles. Geri-RxFiles. 3rd Edition. 2019. Insomnia disorder in older adults. [Internet]. <https://www.rxfiles.ca/RxFiles/uploads/documents/members/GeriRxFiles-Insomnia.pdf>
8. RxFiles. Sleep Insomnia Overview. 2020. [Internet]. <https://www.rxfiles.ca/RxFiles/uploads/documents/members/Cht-psyc-sedatives.pdf>
9. US Department of Veterans Affairs. PBM Academic Detailing Service. Insomnia Disorder. 2019. https://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Academic_Detailing_Educational_Material_Catalog/Ins_Provider_QuickReferenceGuide.PDF

Melatonin

1. Ferracioli-Oda E, Qawasmi A, Bloch M. Meta-analysis: Melatonin for the treatment of primary sleep disorders. *PLoS One* 2013;8:e63773. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/23691095/>
2. Sateia M, Buysse D, Krystal A, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Sleep Med* 2017;13:307-49. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27998379/>
3. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
4. Auger R, Burgess H, Emens J, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders. An American Academy of Sleep Medicine clinical practice guideline. *J Clin Sleep Med* 2015;11:1199-36. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/26414986/>
5. Tools for Practice. Melatonin for sleep: exhausted by other options? 2014. [Internet]. https://www.acfp.ca/wp-content/uploads/tools-for-practice/1409669944_120tftp-melatonininfv2.pdf
6. Zhdanova I, Wurtman R, Balcioğlu A, et al. Endogenous melatonin levels and the fate of exogenous melatonin: age effects. *J Gerontol* 1998;53:293-298. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/18314560/>
7. Lexicomp®. [Internet]. <https://online.lexi.com/lco/action/home>
8. European Medicines Agency. Circadin (melatonin). [Internet]. https://www.ema.europa.eu/en/documents/product-information/circadin-epar-product-information_en.pdf

Diphenhydramine & Doxylamine

1. Sateia M, Buysse D, Krystal A, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. *J Sleep Med* 2017;13:307-49. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/27998379/>
2. VA/DoD Clinical practice guidelines for the management of chronic insomnia disorder and obstructive sleep apnea. 2019. [Internet]. <https://www.healthquality.va.gov/guidelines/CD/insomnia/index.asp>
3. Health Canada. Sleep Aids – Labelling Standard. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/sleep-aids.html>
4. Health Canada. Drug Product Database. [Internet]. Unisom-2 (doxylamine). https://pdf.hres.ca/dpd_pm/00007943.PDF
5. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc* 2019;67:674-694. [Internet]. <https://pubmed.ncbi.nlm.nih.gov/30693946/>
6. Credible Meds. [Internet]. <https://crediblemeds.org/>